The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net revenues | 21,667,212 | - |
| Cost of net revenues | 20,237,807 | - |
| Gross profit | 1,429,405 | - |
| General and administrative | 66,205,669 | - |
| Sales and marketing | 1,212,347 | - |
| Depreciation and amortization | 2,408,462 | - |
| Total operating expenses | 69,826,478 | - |
| Loss from operations | -68,397,073 | - |
| Interest expense, net | 3,703,837 | - |
| Loss on debt extinguishment | -1,353,663 | - |
| Other income | 33,002 | - |
| Total other expense, net | -5,024,498 | - |
| Net loss before income taxes | -73,421,571 | - |
| Net loss | -34,318,204 | -39,103,367 |
| Allowances for credit losses | 65,128 | 200,454 |
| Loss on debt extinguishment | -1,353,663 | - |
| Amortization of debt discount | 406,371 | 33,411 |
| Stock-based compensation | 25,730,184 | 28,708,643 |
| Depreciation | 39,731 | 79,538 |
| Amortization | 763,065 | 1,526,129 |
| Accounts receivable | -996,923 | -362,911 |
| Inventories | -1,539,243 | -487,465 |
| Prepaid expenses | - | 65,001 |
| Deposits | -65,000 | 0 |
| Other assets | 20,999 | -332 |
| Accounts payable | 960,046 | 3,141,897 |
| Accrued expenses and other liabilities | 1,152,507 | 1,145,749 |
| Operating lease liabilities, net | 62,035 | -5,720 |
| Due from / to related parties, net | -134,977 | -61,112 |
| Net cash (used in) provided by operating activities | -1,135,329 | -3,426,447 |
| Investments in capitalized software | 221,085 | 405,059 |
| Cash acquired in business combinations | - | 0 |
| Net cash used in investing activities | -221,085 | -405,059 |
| Proceeds from promissory note | 0 | 615,000 |
| Repayment of seller promissory note | 0 | 137,141 |
| Proceeds from term loan | 228,448 | 703,366 |
| Proceeds from revolving line of credit | 2,924,000 | 17,146,000 |
| Repayment of revolving line of credit | 3,930,015 | 18,697,494 |
| Repayment of merchant cash advance | -599,770 | 234,157 |
| Proceeds from common stock issued pursuant to equity purchase agreement | 2,271,065 | 567,722 |
| Proceeds from common stock issued pursuant to ipo | 0 | 4,000,000 |
| Proceeds from common stock issued pursuant to public offering | 4,534,053 | - |
| Offering costs | -262,643 | -1,208,498 |
| Founders initial contribution | - | 0 |
| Net cash provided by (used in) financing activities | 5,165,138 | 3,223,112 |
| Net change in cash and cash equivalents | 3,808,724 | -608,394 |
| Cash and cash equivalents at beginning of period | 1,028,336 | - |
| Cash and cash equivalents at end of period | 4,228,666 | - |
Wellgistics Health, Inc. (WGRX)
Wellgistics Health, Inc. (WGRX)